Literature DB >> 12741475

Helicobacter pylori infection is associated with greater impairment of cytochrome P-450 liver metabolic activity in anti-HCV positive cirrhotic patients.

Edoardo Giannini1, Alberto Fasoli, Federica Botta, Paola Romagnoli, Federica Malfatti, Bruno Chiarbonello, Mario Mamone, Vincenzo Savarino, Roberto Testa.   

Abstract

Helicobacter pylori gastric infection has been associated with various digestive and extradigestive diseases. In liver disease bacterial infections have been associated with impairment of cytochrome P-450 liver metabolic activity. Moreover, infection by Helicobacter spp. seems to be linked with the development of hepatocellular carcinoma (HCC) in mice. Our aims were to evaluate the influence of H. pylori infection on cytochrome P-450 liver metabolic activity as assessed by means of monoethylglycinexylidide (MEGX) test and to assess the prevalence of H. pylori infection in patients with HCC. Ninety-six hepatitis C virus (HCV) -positive cirrhotic patients, 36 of whom had HCC, were tested for H. pylori infection by means of anti-H. pylori IgG. Patients underwent the MEGX test. Characteristics of the patients were then analyzed on the basis of the presence of H. pylori infection. Seroprevalence of H. pylori infection was similar between cirrhotic patients without (68%) or with (63.8%) HCC. Mean MEGX values were significantly (P < 0.0001) lower in H. pylori infected patients (18.2 +/- 13.9 ng/ml) as compared to the noninfected ones (46.9 +/- 17.1 ng/ml), independently of Child-Pugh's classification. These differences persisted even after subdividing patients according to the presence of HCC. In conclusion, in anti-HCV positive cirrhotic patients H. pylori infection is associated to an impairment of cytochrome P-450 liver metabolic activity. Seroprevalence of H. pylori infection in HCC patients is similar to that observed in tumor-free cirrhotics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12741475     DOI: 10.1023/a:1022861414826

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  47 in total

1.  The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia.

Authors:  A A Igonin; V W Armstrong; M Shipkova; V G Kukes; M Oellerich
Journal:  Clin Chem Lab Med       Date:  2000-11       Impact factor: 3.694

Review 2.  Helicobacter pylori.

Authors:  B J Marshall
Journal:  Am J Gastroenterol       Date:  1994-08       Impact factor: 10.864

3.  Impairment of cytochrome P-450-dependent liver activity in cirrhotic patients with Helicobacter pylori infection.

Authors:  E Giannini; A Fasoli; P Borro; B Chiarbonello; F Malfatti; P Romagnoli; F Botta; E Testa; A Fumagalli; S Polegato; V Savarino; R Testa
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

4.  Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis.

Authors:  R Pellicano; N Leone; M Berrutti; M A Cutufia; M Fiorentino; M Rizzetto; A Ponzetto
Journal:  J Hepatol       Date:  2000-10       Impact factor: 25.083

5.  Helicobacter infection and cirrhosis in hepatitis C virus carriage: is it an innocent bystander or a troublemaker?

Authors:  A Ponzetto; R Pellicano; N Leone; M A Cutufia; F Turrini; W F Grigioni; A D'Errico; P Mortimer; M Rizzetto; L Silengo
Journal:  Med Hypotheses       Date:  2000-02       Impact factor: 1.538

Review 6.  Natural acquisition and spontaneous elimination of Helicobacter pylori infection: clinical implications.

Authors:  H H Xia; N J Talley
Journal:  Am J Gastroenterol       Date:  1997-10       Impact factor: 10.864

Review 7.  Regulation of hepatic cytochrome P-450 during infectious disease.

Authors:  K W Renton; L C Knickle
Journal:  Can J Physiol Pharmacol       Date:  1990-06       Impact factor: 2.273

8.  Hepatic cytochrome P450 is directly inactivated by nitric oxide, not by inflammatory cytokines, in the early phase of endotoxemia.

Authors:  S Takemura; Y Minamiyama; S Imaoka; Y Funae; K Hirohashi; M Inoue; H Kinoshita
Journal:  J Hepatol       Date:  1999-06       Impact factor: 25.083

9.  High prevalence of Helicobacter pylori in liver cirrhosis: relationship with clinical and endoscopic features and the risk of peptic ulcer.

Authors:  S Siringo; D Vaira; M Menegatti; F Piscaglia; S Sofia; M Gaetani; M Miglioli; R Corinaldesi; L Bolondi
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

10.  Role of Helicobacter pylori in cirrhotic patients with peptic ulcer. A serological study.

Authors:  J J Chen; C S Changchien; D I Tai; S S Chiou; C M Lee; C H Kuo
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

View more
  6 in total

1.  Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.

Authors:  Edoardo G Giannini; Federica Malfatti; Federica Botta; Simone Polegato; Emanuela Testa; Alessandra Fumagalli; Mario Mamone; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

2.  CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice.

Authors:  A S Gandhi; T Guo; P Shah; B Moorthy; D S-L Chow; M Hu; R Ghose
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

3.  Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.

Authors:  Edoardo G Giannini; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

4.  Genetic polymorphism of cytochrome P450 (CYP) 1A1, CYP1A2, and CYP2E1 genes modulate susceptibility to gastric cancer in patients with Helicobacter pylori infection.

Authors:  Ujjala Ghoshal; Shweta Tripathi; Sushil Kumar; Balraj Mittal; Dipti Chourasia; Niraj Kumari; Narendra Krishnani; Uday C Ghoshal
Journal:  Gastric Cancer       Date:  2013-05-19       Impact factor: 7.370

Review 5.  Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment.

Authors:  Françoise Stanke-Labesque; Elodie Gautier-Veyret; Stephanie Chhun; Romain Guilhaumou
Journal:  Pharmacol Ther       Date:  2020-07-11       Impact factor: 12.310

6.  Coinfection of Helicobacter pylori and Hepatitis C Virus in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Samragnyi Madala; Kira MacDougall; Balarama Krishna Surapaneni; Robin Park; Mohit Girotra; Anup Kasi
Journal:  J Clin Med Res       Date:  2021-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.